ASTH vs NBIX: fair value comparison
Astrana Health, Inc. and Neurocrine Biosciences, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, NBIX currently sits closer to the top of our ranking by discount to fair value. NBIX carries the stronger quality grade.
| ASTH | NBIX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $36.81 | $135.71 |
| 12-month range | $18.16–$49.81 | $123.10–$185.50 |
| Rank by discount to fair value | #99 of 108 Healthcare | #5 of 108 Healthcare |
| Quality grade | F | A |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: ASTH fair value analysis · NBIX fair value analysis